🇺🇸 FDA
Patent

US 8524901

Compositions and methods for inhibition of the JAK pathway

granted A61KA61K31/155A61K31/506

Quick answer

US patent 8524901 (Compositions and methods for inhibition of the JAK pathway) held by Rigel Pharmaceuticals, Inc. expires Mon Aug 29 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Sep 03 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 29 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
2
CPC classes
A61K, A61K31/155, A61K31/506, A61K31/5377, A61K31/538